Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
HYB New America High Income Fund
ACV Virtus Diversified Income & Convertible Fund
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
CCBC Chino Commercial Bancorp
INGR Ingredion Inc
PROF Profound Medical Corp

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.

Closing Price
Day's Change
0.50 (0.80%)
B/A Size
Day's High
Day's Low

10-day average volume:

Law Office of Alfred G. Yates Jr. PC Announces Investigation of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) and Encourages Investors to Contact the Firm

1:00 pm ET April 13, 2022 (Accesswire) Print

PITTSBURGH, PA / ACCESSWIRE / April 13, 2022 / Law Office of Alfred G. Yates Jr. PC announces that it is investigating Take-Two Interactive Software, Inc. ("Take-Two") (NASDAQ:TTWO) on behalf of the company's shareholders.

On January 10, 2022, Take-Two announced that it had entered into an agreement to acquire Zynga in a cash and stock transaction valued at $9.86 per Zynga share. In connection with the proposed transaction, Take-Two has disclosed that it expects to issue between 50.3 million - 58.5 million shares of common stock to Zynga stockholders who are, as a result, expected to own between 29.6% - 32.8% of the combined company. Following this announcement, shares of Take-Two's common stock declined $21.61 per share, or over 13% in value.

The investigation is focused on whether the members of Take-Two's Board of Directors violated the securities laws or breached their fiduciary duties in connection with the proposed transaction, and whether Take-Two shareholders are being provided with all material information needed to vote on the proposed transaction.

Take-Two shareholders are encouraged to contact attorney Alfred G. Yates Jr. by phone toll free at 1-844-391-5164 or by email at

Alfred G. Yates Jr., Esquire

Law Office of Alfred G. Yates Jr. PC

(412) 391-5164


SOURCE: Law Office of Alfred G. Yates Jr., P.C.

View source version on

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.